By Josh Beckerman
Shares of Hoth Therapeutics rebounded after the company said it has no plans for a public or private offering at this time.
Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday, after falling sharply to a low point of $1.17 from a 52-week high Tuesday. The stock closed up 178%, to $2.28, on Tuesday, after the company reported favorable interim results from a clinical trial.
The company said it was responding to market rumors and shareholder inquiries. It also said enrollment in a clinical trial of HT-001, its lead drug candidate, is proceeding as planned, with all trial sites now active and enrolling participants. HT-001 is designed to treat rash and skin disorders associated with cancer therapy.
"Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt," the company said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 08, 2025 14:44 ET (19:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.